NCT07039916 2026-03-06
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
Immunovant Sciences GmbH
Arcellx, Inc.
Kyverna Therapeutics
iSpecimen Inc